Investigational AKT Inhibitor AZD5363 is Active Against Multiple Tumor Types With AKT1 E17K Mutations

“Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical trial expressly designed to recruit patients with these types of tumors. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Nov. 5–9.

“ ‘The AKT1 E17K genetic mutation was detected in a range of tumor types almost 10 years ago,’ said David M. Hyman, MD, acting director of developmental therapeutics at Memorial Sloan Kettering Cancer Center in New York. ‘Because the mutation is found in only a small fraction of cases of each tumor type and clinical trials have traditionally enrolled patients with only one type of cancer, it was not possible to determine whether the mutation fuels the growth of these tumors and is a viable therapeutic target until the recent advent of basket trials, whereby patients with a range of types of tumor all harboring a defined mutation are enrolled in a single clinical trial.’ “